Analysts Set NeoGenomics, Inc. (NASDAQ:NEO) Target Price at $11.86

Shares of NeoGenomics, Inc. (NASDAQ:NEO) have received an average recommendation of “Hold” from the fourteen research firms that are covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and five have issued a buy rating on the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $11.8571.

A number of brokerages recently commented on NEO. Needham & Company LLC upped their price objective on NeoGenomics from $14.00 to $15.00 and gave the stock a “buy” rating in a research note on Tuesday, February 17th. Piper Sandler raised their target price on NeoGenomics from $12.00 to $13.00 and gave the company an “overweight” rating in a research report on Tuesday, February 24th. Benchmark restated a “hold” rating on shares of NeoGenomics in a research report on Wednesday, February 18th. TD Cowen restated a “buy” rating on shares of NeoGenomics in a research report on Monday, March 16th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of NeoGenomics in a research report on Friday, March 27th.

Institutional Trading of NeoGenomics

Several large investors have recently added to or reduced their stakes in the business. First Horizon Corp increased its position in NeoGenomics by 52.6% in the 4th quarter. First Horizon Corp now owns 2,509 shares of the medical research company’s stock valued at $30,000 after acquiring an additional 865 shares during the period. Aster Capital Management DIFC Ltd increased its position in NeoGenomics by 42.5% in the 3rd quarter. Aster Capital Management DIFC Ltd now owns 3,341 shares of the medical research company’s stock valued at $26,000 after acquiring an additional 997 shares during the period. State of Alaska Department of Revenue increased its position in NeoGenomics by 1.7% in the 4th quarter. State of Alaska Department of Revenue now owns 73,044 shares of the medical research company’s stock valued at $858,000 after acquiring an additional 1,215 shares during the period. Moody National Bank Trust Division increased its position in NeoGenomics by 1.4% in the 3rd quarter. Moody National Bank Trust Division now owns 90,476 shares of the medical research company’s stock valued at $698,000 after acquiring an additional 1,227 shares during the period. Finally, Amalgamated Bank increased its position in NeoGenomics by 3.4% in the 3rd quarter. Amalgamated Bank now owns 37,965 shares of the medical research company’s stock valued at $293,000 after acquiring an additional 1,255 shares during the period. 98.50% of the stock is currently owned by institutional investors and hedge funds.

NeoGenomics Price Performance

Shares of NEO opened at $8.23 on Tuesday. The company has a market cap of $1.07 billion, a P/E ratio of -9.80 and a beta of 1.72. The stock has a fifty day moving average price of $8.87 and a 200 day moving average price of $10.48. The company has a debt-to-equity ratio of 0.41, a current ratio of 4.26 and a quick ratio of 3.94. NeoGenomics has a 12 month low of $4.72 and a 12 month high of $13.74.

NeoGenomics (NASDAQ:NEO) last issued its quarterly earnings data on Tuesday, February 17th. The medical research company reported $0.06 EPS for the quarter, topping analysts’ consensus estimates of $0.04 by $0.02. The firm had revenue of $190.17 million during the quarter, compared to the consensus estimate of $188.25 million. NeoGenomics had a negative return on equity of 3.10% and a negative net margin of 14.85%.The firm’s revenue was up 10.6% on a year-over-year basis. During the same period in the prior year, the business earned $0.04 EPS. On average, research analysts forecast that NeoGenomics will post -0.16 earnings per share for the current year.

About NeoGenomics

NeoGenomics, traded on the Nasdaq under the symbol NEO, is a leading provider of cancer-focused genetic and molecular testing services. Headquartered in Fort Myers, Florida, the company operates an integrated network of CAP-accredited and CLIA-certified laboratories across the United States, Europe and Asia. NeoGenomics delivers diagnostic insights that support oncologists, pathologists and healthcare institutions in the detection, prognosis and treatment of hematologic and solid tumor cancers.

The company’s core service offerings include flow cytometry, immunohistochemistry, fluorescence in situ hybridization (FISH), karyotyping and advanced molecular assays such as next-generation sequencing (NGS) panels and polymerase chain reaction (PCR) tests.